Torticollis

Plagiocephaly and Torticollis Awareness Month

Retrieved on: 
Wednesday, March 27, 2024
Parent, Osteopathy, SAN, Colic, Plagiocephaly, Torticollis, FAAP, OMT

SAN DIEGO, March 27, 2024 /PRNewswire/ -- The Osteopathic Center for Children & Osteopathy's Promise to Children is now looking for infants 4 months old and younger diagnosed with plagiocephaly (flat head syndrome), which affects 47% of infants in the US. If left untreated, this can cause vision problems, muscular tightness, dental issues, & developmental delays. Qualified infants who enroll in this study will receive gentle, hands-on treatment known as Osteopathic Manipulative Treatment (OMT), which has been proven to address the underlying cause of plagiocephaly, reducing its impact on the child's development more than current treatments, such as helmet therapy.

Key Points: 
  • New Study Offering Free Plagiocephaly Treatment (an alternative to helmet therapy) in San Diego, California!
  • SAN DIEGO, March 27, 2024 /PRNewswire/ -- The Osteopathic Center for Children & Osteopathy's Promise to Children is now looking for infants 4 months old and younger diagnosed with plagiocephaly (flat head syndrome), which affects 47% of infants in the US .
  • If left untreated, this can cause vision problems, muscular tightness, dental issues, & developmental delays.
  • "We use OMT to evaluate & treat the whole body, not just one area of concern.

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, General Health, Pharmaceutical, Health, Therapy, RHA, Research, CMS, Fosun International, Education, MD, Investment, Physician, FDA, Marketing, Food, Growth, MBA, Adjustment, Collection, GAAP, Medicare, Webcast, Depreciation, Patient, Tax, OPEX, ASPEN, Lip, Torticollis, Ageing, American Academy, Pharmaceutical industry

Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • Excluding depreciation, amortization, stock-based compensation and restructuring charges, non-GAAP R&D expenses were $18.6 million and $65.5 million, respectively, for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter and full year 2023 RHA Collection revenue of $34.5 million and $128.6 million, respectively.
  • ET on February 28, 2024, to discuss its financial results and provide a corporate update.

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

Retrieved on: 
Friday, February 2, 2024
Neurology, FDA, Public Relations, Investor Relations, Clinical Trials, Communications, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Injection, Spasticity, Government, Therapy, Patient, Safety, Incidence, Torticollis, American Academy, Neurotoxin, Speech, ASPEN, Food, Physician, Total, Muscle weakness, CMS, Death, MHSA, Food and Drug Administration, Hubli railway division, Dysphagia, Pharmaceutical industry

The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.

Key Points: 
  • The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.
  • “Importantly, the real-world clinical results of DAXXIFY from the patients I have injected so far in PrevU, including safety, efficacy and duration, are in-line with those seen in the ASPEN-1 study.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669.

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Retrieved on: 
Thursday, January 18, 2024
AEON, Clavicle, Patient, Heart rate, Research, PTSD, Post-traumatic stress disorder, AB toxin, Stellate ganglion, OLE, Neck, DSM-IV codes, Torticollis, Safety, INA, DBP, Head, Botulinum toxin, Lidocaine, IND, Ptosis, FDA, Toxicity, Rat, SGB, Acute stress disorder, Data, Week, Anatomy, Pharmaceutical industry

IRVINE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.

Key Points: 
  • ABP-450 did not appear to increase treatment-related TEAEs at any dose in the study.
  • These results support further investigation of ABP-450 as a treatment option for patients with CD and other movement disorders.
  • “We are excited to announce positive data from the 52-week OLE portion of the Phase 2 study of ABP-450 for CD.
  • The posters presented by AEON at the TOXINS 2024 conference can be accessed on the Events and Presentations page of the Company’s corporate website.

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Retrieved on: 
Monday, January 8, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Patient, Fosun International, RHA, Collection, Dysphagia, Neurotoxin, FDA, Hubli railway division, Ageing, Torticollis, Therapy, Education, Death, Speech, COVID-19, Adjustment, Spasticity, Growth, Investment, Lip, Finance, PMA, GAAP, Hyaluronic acid

Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.

Key Points: 
  • Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.
  • We wish Dustin the best in his new endeavors.”
    Corporate Updates and Preliminary Q4 and FY 2023 Financial Results:
    Revance expects Q4 2023 preliminary unaudited DAXXIFY revenue to be between $23.5 million and $24.5 million.
  • Full year 2023 preliminary unaudited DAXXIFY revenue is expected to be between $83.5 million and $84.5 million.
  • Revance expects preliminary unaudited fourth quarter 2023 RHA Collection revenue to be between $34 million and $35 million, and full year preliminary unaudited 2023 RHA Collection revenue to be between $128 million and $129 million.

AEON Biopharma Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
AEON, Steps, Migraine, AB toxin, Acquisition, Safety, NYSE, Food, Investment, Common stock, Patient, FDA, NYSE American, Patent, Phase II, Funding, Use, Torticollis, MMD, Pharmaceutical industry, Security (finance)

IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • – Ongoing Phase 2 trial for the preventive treatment of chronic migraine has enrolled over 430 subjects; anticipate completing enrollment in Q4 2023 and announcing topline data in 2H 2024 –
    IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the third quarter ended September 30, 2023 and provided a business update.
  • These data are expected to further support advancing our chronic and episodic migraine programs into pivotal clinical trials.
  • In addition, we continue to evaluate multiple parameters for the planned Phase 3 trial of ABP-450 for the preventive treatment of episodic migraine.
  • Cash, Cash Equivalents and Investments – The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Medical Supplies, Adjustment, FDA, Research, NMPA, Therapy, Physician, SG, Invention, Collection, ASP, CCO, GAAP, R, Senior, Growth, ID, Commercial, Marketing, Webcast, Torticollis, Depreciation, Investment, Patient, RHA, Erica, Fosun Pharma, BLA, Filler (linguistics), Pharmaceutical industry, Video game, Cryptocurrency, Fine chemical, Q3

Revance Therapeutics, Inc. (RVNC), today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Revance Therapeutics, Inc. (RVNC), today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Based on real-world learnings and customer feedback, Revance introduced new competitive pricing for DAXXIFY on September 1, 2023.
  • In September 2023, Revance revised its 2023 GAAP and Non-GAAP operating expense guidance to reflect the company's exit of the OPUL payments business.
  • ET on November 8, 2023, to discuss its financial results and provide a corporate update.

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

Retrieved on: 
Thursday, October 26, 2023
Cosmetics, Medical Supplies, Retail, Health, Other Health, Pharmaceutical, Biotechnology, Patient, Hubli railway division, FDA, Dermatology, Physician, Invention, Spasticity, Skin, Research, Speech, Torticollis, Dysphagia, AI, Neurotoxin, Muscular system, Death, Fine chemical, Vaccine, Dietary supplement, Pharmaceutical industry

TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.

Key Points: 
  • TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.
  • The entrants were then evaluated against a number of key factors, including originality, efficacy, ambition, and impact.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Merz Therapeutics Hosts Over 300 International Healthcare Professionals at its First Global “Merz Expert Connect Summit 2023”

Retrieved on: 
Friday, October 6, 2023
Medical Devices, Health, Hospitals, Health Technology, Pharmaceutical, Biotechnology, Stroke, Research, Medicine, AB toxin, Summit, Neurology, Travel, Patient, Therapy, Education, International Material Data System, Merz, DSM-IV codes, Cerebral palsy, Torticollis, Neurotoxin, Spasticity, Hypersalivation, Physician, Nursing

Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today.

Key Points: 
  • Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today.
  • More than 300 international experts in rehabilitation medicine and neurology will attend the event in Berlin from 6–7 October.
  • The “Merz Expert Connect Summit” is the largest global stand-alone event of its scale in the company’s history.
  • The program of the “Merz Expert Connect Summit” features more than 27 lectures by international thought leaders on a variety of relevant topics.

Unlocking the Potential: Global Dystonia Drugs Market Set to Grow at 5.3% CAGR by 2027 - Analyzing Emerging Markets and Healthcare Advancements - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023
Health, Pharmaceutical, Growth, Torticollis, Pharmacist, Dystonia, Drug, Research, Pharmacy, GABAergic, Pharmaceutical industry

Among these, GABAergic agents have the largest market share, attributed to their effectiveness in treating dystonia, especially cervical dystonia.

Key Points: 
  • Among these, GABAergic agents have the largest market share, attributed to their effectiveness in treating dystonia, especially cervical dystonia.
  • The pharmaceutical industry's discovery of highly effective GABAergic agent medications for dystonia treatment is further driving the growth of this segment.
  • The injectable segment holds a significant market share due to innovations in parenteral dosing and increased research and development for botulinum injections.
  • The drug stores and retail pharmacies segment dominates the market, benefiting from its extensive distribution network and longstanding presence as a convenient channel for drug distribution.